Epigenetic Alterations in Hepatocellular Carcinoma: Mechanisms and Biomarkers for Precision Therapy

Area of Science:

• Oncology
• Epigenetics
• Hepatocellular Carcinoma Research

Background:

• Hepatocellular carcinoma (HCC) is a major global cancer killer, influenced by genetic mutations and epigenetic changes.
• Aberrant DNA methylation, histone modifications, and noncoding RNAs (ncRNAs) are key drivers of HCC initiation, progression, and treatment resistance.
• Epigenetic alterations regulate oncogenic pathways, immune evasion, and tumor heterogeneity in HCC.

Purpose of the Study:

• To review recent advancements in understanding the epigenetic landscape of HCC.
• To identify potential biomarkers for early detection and prognosis of HCC.
• To evaluate emerging epigenetic therapies for HCC treatment.

Main Methods:

• Literature review of recent research on HCC epigenetics.
• Analysis of epigenetic alterations in hepatocarcinogenesis.
• Evaluation of preclinical and clinical data for epigenetic therapies.

Main Results:

• Epigenetic modifications are crucial in HCC development, impacting oncogenic pathways and immune responses.
• Emerging epigenetic therapies, including DNMT, HDAC, BET inhibitors, and ncRNA-based strategies, show promise.
• Clinical translation of these therapies is hindered by modest efficacy, limited trial data, adverse events, and poor patient selection.

Conclusions:

• Epigenetic alterations are central to HCC and present druggable targets.
• While promising, epigenetic therapies for HCC face challenges in clinical application.
• Further research and biomarker-guided strategies are essential for effective HCC treatment.